Beware the false prophet, page-2

Bone scans and PSA levels? Serious. Try the below study RBX.


Form the Lancet Oncol. 2015 Jul

"The primary endpoint was the proportion of patients with an abscopal response (defined as at least a 30% decrease in the longest diameter of the best responding abscopal lesion). Secondary endpoints were safety and survival.....

FINDINGS:
"From April 7, 2003, to April 3, 2012, 41 patients with metastatic cancer were enrolled. In stage 1 of the Simon's two-stage design, ten patients were enrolled: four of the first ten patients had abscopal responses. Thus, the trial proceeded to stage 2, as planned, and an additional 19 patients were enrolled. Due to protocol amendments 12 further patients were enrolled. Abscopal responses occurred in eight (27·6%, 95% CI 12·7-47·2) of the first 29 patients, and 11 (26·8%, 95% CI 14·2-42·9) of 41 accrued patients (specifically in four patients with non-small-cell lung cancer, five with breast cancer, and two with thymic cancer). " (https://www.ncbi.nlm.nih.gov/pubmed/26095785?dopt=Abstract)

Their criteria

• Patients must have at least 3 distinct measurable metastatic sites at least 1 cm of larger in their largest diameter.https://clinicaltrials.gov/ct2/show/NCT02474186